Recordati

October 10, 2018

Mid-cap investors see Eastern promise in the third quarter

Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap players.

Mid-cap investors see Eastern promise in the third quarter

Shikeda masks slow second quarter for buyouts

Recordati deal points the way to a new private equity sweet spot

Back to the future for small caps, but not all benefit

Strong small cap performance drives second-quarter gains

Astrazeneca's dealing cannot mask its problems

Event – Erytech looks to pancreatic cancer data for uplift

Upcoming events: High-risk readouts for Erytech and Heron

Erytech wraps up successful pivotal study with leukaemia therapy

Upcoming events: Pivotal data for Seattle Genetics and Erytech

Investors waking up to Nymox

Latest Reports

Vantage 2020 Preview

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

Editor's Picks

What makes a great year for takeovers?

Surprise! There’s a tumour in which Keytruda doesn’t work

Gene therapy clinical holds take centre stage

Plenty of choice remains for buyers of gene therapy

Uncovering biopharma’s hidden treasures